SCHEMBL285827

SCHEMBL285827

CC(C)CCOC([O])CC(C)C

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4963064 0.82 ALDH1A1 (0.42) ALDH1A1CA12CA1CA2CA9
SCHEMBL5961045 0.80 ALDH1A1 (0.41) ALDH1A1CA12CA1CA2CA9
SCHEMBL1259885 0.76 ALDH1A1 (0.38) ALDH1A1CA12CA1CA2CA9
SCHEMBL497154 0.76 DNM1 (0.42) CA12CA1CA2CA9
SCHEMBL1402189 0.76
SCHEMBL5961135 0.75 OPRM1 (0.39) ALDH1A1CA1
SCHEMBL8005450 0.74 ALDH1A1 (0.36) ALDH1A1
SCHEMBL6018309 0.71 MAPT (0.31)
SCHEMBL1246945 0.70 CA12 (0.37) ALDH1A1CA12CA1CA2CA9
SCHEMBL6030032 0.70 LMNA (0.36) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394186-B2 Porphyrazine coloring matter, ink composition and colored product NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-03-12 US disclosed
US-8163728-B2 Pyrazoles HOFFMANN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2427455-A1 ISOXAZOLE-PYRAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
EP-2427456-A1 ISOXAZOLE-PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
EP-2427458-A1 ISOXAZOLE-PYRIDAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed
US-20110144097-A1 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 US disclosed
WO-2011069934-A1 2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-16 WO disclosed
US-20110090278-A1 Porphyrazine Coloring Matter, Ink Composition And Colored Product NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-04-21 US disclosed
US-20110046122-A1 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES SIENA BIOTECH S.P.A. (IT) 2011-02-24 US disclosed
US-20060167001-A1 Pyridazinone-derivatives as pde4 inhibitors ALTANA PHARMA AG (DE) 2006-07-27 US disclosed
US-20060094710-A1 Piperidine-pyridazones and phthalazones as pde4 inhibitors ALTANA PHARMA AG (DE) 2006-05-04 US disclosed
EP-1086096-B1 BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS ALTANA PHARMA AG (DE) 2003-07-23 EP disclosed
EP-1086096-A1 BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2001-03-28 EP disclosed
EP-1075476-A1 NOVEL BENZIMIDAZOLES AND BENZOXAZOLES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2001-02-14 EP disclosed
WO-1999064414-A1 BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1999-12-16 WO disclosed
WO-1999057115-A1 NOVEL BENZIMIDAZOLES AND BENZOXAZOLES BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1999-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094710-A1 Piperidine-pyridazones and phthalazones as pde4 inhibitors PDE4A, PDE4B, PDE3A ALDH1A1 88/4885CA12 4223/4885CA1 3270/4885
US-20060167001-A1 Pyridazinone-derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B ALDH1A1 470/4885CA12 4714/4885CA1 4605/4885
US-20110046122-A1 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES BACE2, BACE1, APP ALDH1A1 195/4885CA12 1238/4885CA1 452/4885
US-20120053200-A1 BACE 2 INHIBITORS BACE2, BACE1, PSEN2 ALDH1A1 756/4885CA12 2260/4885CA1 1688/4885
US-20110144097-A1 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES BACE2, BACE1, APP ALDH1A1 241/4885CA12 2160/4885CA1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.